RxDoctor Payments Data

Ramon Flores Gonzalez, MD

Neurology · Miami, FLNPI 1114389855

Payments from drug & device makers

$436,303in general payments, 2019–2025

Across 70 payments — averaging $6232.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$292K
  • TG Therapeutics, Inc.$98K
  • Hoffmann-la Roche Limited$43K
  • EMD Serono, Inc.$2K
  • Sanofi$197
  • Novartis$168
  • plus $247 from 4 others

What the payments were for

  • Consulting fees$2,00065%
  • Food & beverage$1,06135%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$436,303 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$22,421
Medicare patients
71
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab34$395,072
TecfideraDimethyl Fumarate14$130,108
MayzentSiponimod12$117,540
Plegridy PenPeginterferon Beta-1a14$113,407
Teriflunomide11$28,331
Dalfampridine ErDalfampridine37$21,597
MyrbetriqMirabegron12$5,377
Baclofen85$2,091
Dimethyl Fumarate15$1,892
Gabapentin79$1,600
Fesoterodine Fumarate ErFesoterodine Fumarate11$991
Modafinil17$936
Duloxetine Hcl25$667
Clonazepam40$482
Carbamazepine20$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$117$130,10814 claims
NovartisMayzent$168$117,54012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →